| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Throughout the last three months, 7 analysts have evaluated GE HealthCare Techs (NASDAQ:GEHC), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 1 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 1 | 0 | 0 |
| 2M Ago | 3 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $100.14, a high estimate of $110.00, and a low estimate of $86.00. Witnessing a positive shift, the current average has risen by 7.1% from the previous average price target of $93.50.
In examining recent analyst actions, we gain insights into how financial experts perceive GE HealthCare Techs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Roman | Goldman Sachs | Announces | Neutral | $87.00 | - |
| Craig Bijou | B of A Securities | Lowers | Neutral | $86.00 | $94.00 |
| Anthony Petrone | Mizuho | Lowers | Buy | $105.00 | $110.00 |
| Anthony Petrone | Mizuho | Raises | Buy | $110.00 | $96.00 |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $100.00 | $93.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $103.00 | $88.00 |
| David Toung | Argus Research | Raises | Buy | $110.00 | $80.00 |
Capture valuable insights into GE HealthCare Techs's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on GE HealthCare Techs analyst ratings.
GE HealthCare Technologies Inc is a globally medical technology, pharmaceutical diagnostics, and digital solutions innovator company. It has four operating segments; Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). It earns a majority of its revenue from the Imaging segment.
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining GE HealthCare Techs's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -1.21% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: GE HealthCare Techs's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 8.04%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): GE HealthCare Techs's ROE stands out, surpassing industry averages. With an impressive ROE of 5.14%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): GE HealthCare Techs's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.16%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: GE HealthCare Techs's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.31, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: GEHC
